We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Early Detection of miRNAs in Maternal Blood Could Predict Preeclampsia

By LabMedica International staff writers
Posted on 17 Jul 2024

Preeclampsia (PE) significantly contributes to increased maternal morbidity and mortality globally, with notably high incidences in the United States where it impacts 2–8% of pregnancies. More...

This condition often leads to premature births and subsequent health issues for infants. Now, a new study indicates that early detection of specific microRNAs (miRNAs) contained in vesicles could enable the prediction of preeclampsia in pregnant individuals before the appearance of clinical symptoms.

Conducted by researchers at UCLA Health (Los Angeles, CA, USA), this study highlights the potential of a distinct set of miRNAs within extracellular vesicles (EVs)—small particles that facilitate cellular communication—as a noninvasive biomarker for preeclampsia. The analysis involved 33 participants, including a control group of seven non-pregnant women and a subgroup of 12 women with healthy pregnancies. The study also included 14 women exhibiting symptoms of preeclampsia, emphasizing early detection and prediction. Women with preeclampsia exhibited different levels of miRNAs in EVs early in pregnancy compared to those with healthy pregnancies. The research identified 148 miRNAs with varied abundances in the EVs of women with preeclampsia: 12 in greater quantities and 135 in reduced quantities compared to EVs from healthy pregnancies, showing distinct group patterns in EVs from women with the condition.

These miRNAs, detectable in blood samples from pregnant women with preeclampsia as early as the first to the second trimester, exhibit a specific pattern throughout pregnancy that shifts upon the onset of preeclampsia. Several of these miRNAs originate from the placenta and function as communicators between the placenta and other bodily organs. The researchers suggest that this panel of miRNAs could predict the development of preeclampsia symptoms, particularly those of late-onset preeclampsia. The findings published in the journal Scientific Reports propose a future where miRNAs within EVs could revolutionize the way maternal health is monitored and managed, serving as noninvasive biomarkers for the early detection of preeclampsia and enhancing understanding of the disease's pathophysiology.

“It is critical that we take steps toward early detection and prevention of pre-eclampsia,” said Dr. Sherin U. Devaskar, MD, executive chair of the Department of Pediatrics and physician-in-chief at UCLA Mattel Children’s Hospital, who led the study. “It continues to be the leading cause of maternal mortality and morbidity worldwide, and our findings underscore the potential to address this persistent public health concern.”

Related Links:
UCLA Health


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.